| Ticker: | PRLD |
| Current Price: | $3.45 |
| % Daily Change: | -1.99% |
| Volume (1,000s): | 262.09 |
| Average Volume (1,000s): | 441.76 |
| Market Cap (M): | $199.69 |
| 1/2/2024 Price: | $2.90 |
| Change Since Inception: | 18.97% |
Prelude Therapeutics Incorporated
175 Innovation Boulevard
Wilmington, DE 19805
United States
Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s diverse pipeline is comprised of highly differentiated, potentially best-in-class proprietary small molecule compounds aimed at addressing clinically validated pathways for cancers with selectable underserved patients. Prelude’s pipeline includes three candidates currently in clinical development: PRT3789 an IV administered, potent and highly selective SMARCA2 degrader, PRT2527, a potent and highly selective CDK9 inhibitor, PRT3645 a next generation CDK4/6 inhibitor, and a preclinical oral candidate targeting SMARCA2.